STOCK TITAN

Merus N.V. Common Shares - $MRUS STOCK NEWS

Welcome to our dedicated page for Merus N.V. Common Shares news (Ticker: $MRUS), a resource for investors and traders seeking the latest updates and insights on Merus N.V. Common Shares stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Merus N.V. Common Shares's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Merus N.V. Common Shares's position in the market.

Rhea-AI Summary
Merus N.V. announces financial results for Q2 and provides business update. Petosemtamab granted Fast Track Designation for head & neck cancer. Breakthrough Therapy Designations granted for Zeno in lung and pancreatic cancer. Merus plans to initiate phase 3 trial of petosemtamab in mid-2024. Enrollment continues for Zeno and MCLA-129 trials. Merus working with Incyte Corporation on bispecific antibody programs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.34%
Tags
-
Rhea-AI Summary
Merus N.V., a clinical-stage oncology company, announced that two abstracts featuring updated interim clinical data for its targeted bispecific antibody, zenocutuzumab (Zeno), have been selected for presentation at the European Society for Medical Oncology Congress (ESMO) 2023. The abstracts will focus on NRG1+ non-small cell lung cancer (NSCLC) and pancreatic ductal adenocarcinoma (PDAC). Merus is currently enrolling patients for the phase 1/2 eNRGy trial to assess the safety and anti-tumor activity of Zeno monotherapy in NRG1+ cancer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.83%
Tags
none
-
Rhea-AI Summary
Merus N.V. has received Breakthrough Therapy Designation (BTD) from the FDA for zenocutuzumab (Zeno) for the treatment of NRG1+ non-small cell lung cancer. This follows previous designations for pancreatic cancer and metastatic solid tumors harboring NRG1 gene fusions. Merus plans to engage in discussions with the FDA for expedited development and review, and will provide updates on the potential Biologics License Application (BLA) submission.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.97%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.19%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.64%
Tags
management
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.68%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.58%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.07%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.42%
Tags
none
Merus N.V. Common Shares

Nasdaq:MRUS

MRUS Rankings

MRUS Stock Data

2.69B
42.51M
7.18%
88.09%
5.89%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
3584 CM UTRECHT

About MRUS

merus is developing best-in-class therapeutics to treat and potentially cure cancer patients. our most advanced development programs use the biclonics® format. biclonics® are capable of simultaneously attacking tumors in multiple ways. for example by activating the immune system to kill tumor cells and directly inhibiting tumor cell growth and survival pathways.